A jury in the New York City on Friday has awarded a $325 million verdict against Jonson & Jonson over claims of asbestos in its talc caused plaintiff Donna Olson to develop mesothelioma.
After a 4-month trial, jurors ordered the company to pay $300 million in punitive damages, $20 million for Olson’s past and future pain, plus $5 million to her husband for loss of consortium. This is so far the largest award against J&J in it's talc litigation. Last summer, jurors in St. Louis handed over a $4.69 billion decision against the company after a trial that combined the claims of 22 women. J&J said it would appeal. Before that, a California plaintiff scored a $417 million verdict, but J&J won its appeal in that case.
In addition to the talc litigation, J&J also faces the Oklahoma opioid trial and is the only remaining defendant after Teva and Purdue settled for a total of $355 million. In opening remarks last week, Oklahoma attorney general Mike Hunter accused Johnson & Johnson of a “deceitful, multibillion-dollar brainwashing campaign.” J&J denied wrongdoing and argues it marketed opioid painkillers responsibly.
More about the New York City Case
After a 4-month trial, jurors ordered the company to pay $300 million in punitive damages, $20 million for Olson’s past and future pain, plus $5 million to her husband for loss of consortium. This is so far the largest award against J&J in it's talc litigation. Last summer, jurors in St. Louis handed over a $4.69 billion decision against the company after a trial that combined the claims of 22 women. J&J said it would appeal. Before that, a California plaintiff scored a $417 million verdict, but J&J won its appeal in that case.
In addition to the talc litigation, J&J also faces the Oklahoma opioid trial and is the only remaining defendant after Teva and Purdue settled for a total of $355 million. In opening remarks last week, Oklahoma attorney general Mike Hunter accused Johnson & Johnson of a “deceitful, multibillion-dollar brainwashing campaign.” J&J denied wrongdoing and argues it marketed opioid painkillers responsibly.
More about the New York City Case
No comments:
Post a Comment